to program for UGN-XXX Thank cancer. call, you, quarterly progress patients with invasive risk our Jeff. we've non-muscle our make bladder Since last intermediate on continued low-grade
patients this third Phase in of We this of for in a and to providing sites the trial, half trial ATLAS in are remainder handful a our patients. about updates ATLAS treatment to with second enrollment investigational primarily to as We work U.S. look the the enrolling Eastern bring three Europe. we forward in the Europe, year Israel you in
to at-home initiate to demonstrating installation further study differentiation This health enroll In of goal addition planning installation We to home feasible TURBT. would plan are a in patients study receive is who qualified method arm the a XX of at-home a is half potential administered small of to reinforcing UGN-XXX of XXX, and administration a expected ATLAS, its XXXX. initiate to that single with provider. by approximately from we second
goal know, therapy intermediate a therapeutic to UGN-XXX can risk cancer that function demonstrate with is low alternative As for primary non-muscle as program our bladder grade patients. you non-surgical invasive
occurrence, procedures. patients published the complications Dr. is Gary manuscript Journal the associated Urology, from would that in I current avoid which Steinberg non-surgical be with journal the the of which option and and available TURBT disease to risks the physicians treatment risk had complications of of of challenges a edition will NMIBC. both potential currently approach, TURBT to procedure. print as The recently desire manuscripts come of repeated a of for high patients highlighted repeated the is rate and TURBT, the the identify which the and to in Importantly, help addresses online the well July non-surgical recurrent as including alternatives
presentation the at submitted AUA for abstracts that September. recently National Annual notification the in the accepted received we We also multiple Meeting
performed living extensive This and clinical Carolina, both course with understanding patients course work, We unmet disease with of risk have North UCLA aimed and aspects University partnership multiple better need which experience. of research is patient the and been conducting intermediate at of of the NMIBC. contemporary the groups the in explores
will how Turning will the to evidence-based drug’s across We believe practice this Jelmyto. physicians registry are program Jelmyto, optimize a enable look to information real a we us and this about to with that look as at are launching U.S. gain world information use collect patients treating be treatment we invaluable in
better on One this registry administration, the experience patient nephrostomy understand the of us and things is of the has will to outcomes. the and prevalence the impact program help what clinical
this gaining too Nephrostomy we via adverse label. to easier come be our to practice and It's intriguing in hypothesize seems observed in administration patients with or doctors this OLYMPUS were administration. future. While Tube, it and the treating clinical treated trial, events catheter And is some could And Tube in physician our none to early The the Nephrostomy of Tube numbers on urethral Nephrostomy mitigate way are outcomes. for to via treatment was patient momentum. talk it practice. of of topic part they know the the More that also be patients
talk to earlier want I about Next pipeline. our
expand mentioned, we high continue our to pipeline programs Liz and advanced grade As disease. immuno-oncology for
patients a combined there risk non-muscle being agonist and or with of and RTGel TLR an rapid Our often between for invasive UGN-XXX significant cancer disease. low and is High-grade is differences anti-CTLA-X progression. combination non-muscle our high-grade significant life and our invasive UGN-XXX program, bladder initially of potentially grade UGN-XXX, disease that We've discussed X/X grade threatening malignancy are and bladder we developed technology cancer. by antibody high have aggressive with recurrence both zalifrelimab characterized
immunotherapy immunotherapies for which non-muscle population. using with this or the to Calmette-Guérin strong treatment bladder of invasive Bacillus Some patients high-grade the cancer respond explained BCG, for exploring rationale patient
has programs applied which to XXX locally data of demonstrated date, encouraging the immunotherapy. non-clinical Our potential support combinatorially
Anderson we designs. MD trial providing next look this and us Our for trials. their updates allows in with forward work expertise we clinical collaboration on to program to steps innovative And leverage as
of primary rate U.S. And local gel technology to Johns GBM academic other to or that, a was program recently on with our RTGel technology, overview. over immuno-oncology. continuing RT of the Molly five exploring medicines options. potential pursue Hopkins tumor a in potential also which turn around which preclinical XX,XXX We the forward a sponsor modulation novel in investigate significant most cases is common The year brain malignant options announced a year We of This initial focus may with of therapeutic of unmet diagnosed combined for for to to origin difference. the this and patients tumor intend call is with with brain financial combination with treatment difficult our in disease leverage centers, in research aggressive Glioblastoma chemotherapy. with less than setting inhibitors It each with examining University to most look who combination area in X%. diseases I'd the collaborations need, immune options, the an explore with in potential treat and And in available includes agreement for expanding a of followed and Multiforme GBM. to focus we technology by our radiation make treatment RTGel to survival like Molly? surgery, a may is this where checkpoint limited with our the agreement
